Specify a stock or a cryptocurrency in the search bar to get a summary
AnGes Inc
4563AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan. Address: Saito Bio-Incubator, Ibaraki, Japan, 567-0085
Analytics
WallStreet Target Price
96 718.45 JPYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4563
Dividend Analytics 4563
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4563
Stock Valuation 4563
Financials 4563
Results | 2019 | Dynamics |